Drug Trial Radar · NCT03806309
OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC
Last checked: Nov 19, 2026Latest source record: Jul 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
106
Planned (sponsor's estimate)
Start
Apr 10, 2021
Primary completion
Dec 9, 2024
Study completion Dec 2025
Sponsor
- Lead sponsor
- GERCOR - Multidisciplinary Oncology Cooperative GroupAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- OSE Immunotherapeutics
- First posted
- Jan 16, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
TEDOPAM is a randomized (1.1.1) non-comparative phase II study. This study will assess the efficacy and safety of OSE2101 alone or in combination with nivolumab followed by FOLFIRI reintroduction, versus FOLFIRI as maintenance therapy in patients with advanced PDAC after induction therapy with FOLFIRINOX.
Conditions
- Pancreatic Ductal Adenocarcinoma
- Locally Advanced Cancer
- Metastatic Cancer
Interventions
FOLFIRIDrug
Intravenous (IV); folinic acid 400 mg/m\^2, irinotecan 180 mg/m\^2, 5-FU bolus 400 mg/m\^2 and continuous infusion 2,400 mg/m\^2
OSE2101Drug
subcutaneous injection on days 1 and 15, every 4 weeks for 6 doses then every 8 weeks until month 12 and then every 12 weeks for a maximum treatment duration of 24 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: At 12 months
Locations
28 sites in 1 country. Site status is shown where the registry gives one.
Clinique de l'Europe
Amiens, France
Hôpital Sud CHU Amiens
Amiens, France
CH Beauvais
Beauvais, France
CHRU Jean Minjoz
Besançon, France
Clinique Tivoli Ducos
Bordeaux, France
CHU Morvan
Brest, France
GHPSO Site de Creil
Creil, France
Hôpital Henri Mondor
Créteil, France
Centre Georges François Leclerc
Dijon, France
CHU Dijon
Dijon, France
CHRU Lille
Lille, France
centre Léon Bérard
Lyon, France
Hôpital Edouard Herriot
Lyon, France
Hôpital la Croix Rousse
Lyon, France
Hôpital Lyon Sud Hospices Civils de Lyon
Lyon, France
Hôpital Privé Jean Mermoz
Lyon, France
Hôpital Européen
Marseille, France
Institut Paoli Calmette
Marseille, France
Hôpital Pitié Salpêtrière
Paris, France
Hôpital Saint Antoine
Paris, France
Institut Mutualiste Montsouris
Paris, France
CHU Poitiers
Poitiers, France
CHU Robert Debré
Reims, France
Institut Curie
Saint-Cloud, France
Centre Paul Strauss
Strasbourg, France
Clinique Pasteur
Toulouse, France
Hôpital TROUSSEAU
Tours, France
Insitut de Cancérologie de Lorraine
Vandœuvre-lès-Nancy, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.